These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10695598)

  • 1. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives.
    Shapiro S; Rosenberg L; Hoffman M; Truter H; Cooper D; Rao S; Dent D; Gudgeon A; van Zyl J; Katzenellenbogen J; Baillie R
    Am J Epidemiol; 2000 Feb; 151(4):396-403. PubMed ID: 10695598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa).
    Shapiro S; Rosenberg L; Hoffman M; Kelly JP; Cooper DD; Carrara H; Denny LE; du Toit G; Allan BR; Stander IA; Williamson AL
    Cancer Causes Control; 2003 Jun; 14(5):485-95. PubMed ID: 12946044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case control study of breast cancer risk and exposure to injectable progestogen contraceptives. Methods and patterns of use among controls.
    Bailie R; Katzenellenbogen J; Hoffman M; Schierhout G; Truter H; Dent D; Gudgeon A; van Zyl J; Rosenberg L; Shapiro S
    S Afr Med J; 1997 Mar; 87(3):302-5. PubMed ID: 9137342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of once-a-month combined injectable contraceptives.
    Sang GW
    Contraception; 1994 Apr; 49(4):361-85. PubMed ID: 8013220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation.
    Koetsawang S
    Contraception; 1994 Apr; 49(4):387-98. PubMed ID: 8013221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
    Balogun OR; Raji HO
    Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestogen-only contraceptives and cancer risk.
    La Vecchia C; Franceschi S
    Eur J Cancer Prev; 2002 Apr; 11(2):113-5. PubMed ID: 11984127
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital.
    Ojule JD; Oriji VK; Okongwu C
    Niger J Med; 2010; 19(1):87-95. PubMed ID: 20232762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestogen-only oral contraceptives and risk of breast cancer in New Zealand.
    Skegg DC; Paul C; Spears GF; Williams SM
    Cancer Causes Control; 1996 Sep; 7(5):513-9. PubMed ID: 8877048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined oral contraceptive. Risks and adverse effects in perspective.
    Bagshaw S
    Drug Saf; 1995 Feb; 12(2):91-6. PubMed ID: 7766340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study.
    Urban M; Banks E; Egger S; Canfell K; O'Connell D; Beral V; Sitas F
    PLoS Med; 2012; 9(3):e1001182. PubMed ID: 22412354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogen-only injectable contraceptive: Acceptor prevalence and client experience at Sagamu, Nigeria.
    Akadri AA; Odelola OI
    Niger Postgrad Med J; 2017; 24(3):178-181. PubMed ID: 29082908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral contraceptives: risks and benefits.
    Thorogood M; Villard-Mackintosh L
    Br Med Bull; 1993 Jan; 49(1):124-39. PubMed ID: 8324603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral-contraceptive use and the risk of breast cancer.
    Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
    N Engl J Med; 1986 Aug; 315(7):405-11. PubMed ID: 3736618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa.
    Smit J; McFadyen L; Zuma K; Preston-Whyte E
    Soc Sci Med; 2002 Nov; 55(9):1511-22. PubMed ID: 12297238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.